Skip to main content
Premium Trial:

Request an Annual Quote

Motorola Completes Test of eSensor DNA Detection System

NEW YORK, May 2 – Motorola has tested its eSensor DNA detection system at a UCLA hospital-based genetic testing laboratory to study disease-associated genetic variations, the company said Wednesday.

Wayne Grody, the director of the UCLA molecular genetics laboratory, used eSensor to detect genetic mutations associated with hereditary hemochromatosis—the most common single mutation-based genetic disease. The results showed that the eSensor worked to verify genetic diseases in all of the 33 patients tested. 

"Not only did we achieve 100% concordance on 33 patient specimens for hemochromatosis genotyping, but we were able to demonstrate that our platform is an appropriate one for use in the clinical molecular diagnostics laboratory," Daniel Farkas, director of clinical diagnostics for Motorola Life Sciences, said in a statement.

The eSensor, made by Motorola’s Clinical Micro Sensors business unit in Pasadena, Calif., uses organic molecules to form an electronic circuit to detect up to 36 DNA and RNA targets at a time. The device is designed to provide an effective low-cost method to perform genetic tests for a variety of diseases. It requires amplification by PCR, but is designed for quick desktop DNA analysis.

The eSensor is still undergoing additional testing. Motorola eventually plans to make a more advanced version that could read whole blood samples and could be inexpensive enough for any medical diagnostic lab.   
The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.